MarketPeel
Insider Trading Intelligence
Pricing
…
RM

Ram Mukunda

IGC
CEO · IGC PHARMA, INC. · CIK 0001047575
FILING MIX · LIFETIME60%/40%
BUYS
40
SELLS
27
TOTAL VALUE
$979.2K
COMPANIES
1
ACTIVE SINCE
Jun 2020
HOLDINGS NOW
6,875,563
AVG SELL PX
$2.26
TRADE KIND
SHOWING 67 / 67
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Ram Mukunda, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+100.00%-17.03%+1.05%-18.08%-18.08%—
14d2+100.00%-17.05%+1.57%-18.63%-18.63%—
30d2+100.00%-17.16%+3.58%-20.75%-20.75%—
60d2+100.00%-24.26%+5.48%-29.74%-29.74%—
90d2+100.00%-20.46%+8.49%-28.96%-28.96%—
180d2+100.00%-28.23%+17.33%-45.55%-45.55%—
1y2+100.00%-44.47%+21.20%-65.67%-65.67%—
2y2+100.00%-82.05%+10.96%-93.00%-93.00%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
IGC · 6,875,563 shares · as of Jun 30, 2026
01,718,8913,437,7825,156,6726,875,563202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 40 buys / 27 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
2,226,475$0.27$601.1K6,875,563Jun 30, 2026Jun 30, 2026 ↗View →
IGC
IGC PHARMA, INC.
SALE
CEO
33,332——33,334Apr 1, 2026Apr 6, 2026 ↗View →
IGC
IGC PHARMA, INC.
SALE
CEO
323,077——676,925Apr 1, 2026Apr 6, 2026 ↗View →
IGC
IGC PHARMA, INC.
PURCHASE
CEO
323,077$0.26$84.0K4,649,088Apr 1, 2026Apr 6, 2026 ↗View →
IGC
IGC PHARMA, INC.
SALE
CEO
333,333——0Apr 1, 2026Apr 6, 2026 ↗View →
IGC
IGC PHARMA, INC.
SALE
CEO
16,667——0Apr 1, 2026Apr 6, 2026 ↗View →
IGC
IGC PHARMA, INC.
PURCHASE
CEO
16,667——877,419Apr 1, 2026Apr 6, 2026 ↗View →
IGC
IGC PHARMA, INC.
PURCHASE
CEO
33,332——910,751Apr 1, 2026Apr 6, 2026 ↗View →
IGC
IGC PHARMA, INC.
PURCHASE
CEO
333,333——4,326,011Apr 1, 2026Apr 6, 2026 ↗View →
IGC
IGC PHARMA, INC.
PURCHASE
CEO
50,000——860,752Feb 3, 2026Feb 4, 2026 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
16,667——16,667Feb 3, 2026Feb 4, 2026 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
66,666——66,666Feb 3, 2026Feb 4, 2026 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
1,500,000——1,500,000Oct 17, 2025Oct 17, 2025 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
3,000,000——3,000,000Oct 17, 2025Oct 17, 2025 ↗View →
IGC
IGC PHARMA, INC.
SALEGRANT
Gift
100,000——3,992,678Oct 17, 2025Oct 17, 2025 ↗View →
IGC
IGC PHARMA, INC.
SALE
CEO
233,333——233,333Mar 13, 2024Mar 18, 2024 ↗View →
IGC
IGC PHARMA, INC.
PURCHASE
CEO
333,333——2,908,093Mar 13, 2024Mar 18, 2024 ↗View →
IGC
IGC PHARMA, INC.
PURCHASE
CEO
16,667——810,752Mar 13, 2024Mar 18, 2024 ↗View →
IGC
IGC PHARMA, INC.
PURCHASE
CEO
251,250——3,726,011Mar 13, 2024Mar 18, 2024 ↗View →
IGC
IGC PHARMA, INC.
SALE
CEO
16,667——0Mar 13, 2024Mar 18, 2024 ↗View →
IGC
IGC PHARMA, INC.
SALE
CEO
333,333——0Mar 13, 2024Mar 18, 2024 ↗View →
IGC
IGC PHARMA, INC.
PURCHASE
CEO
16,667——794,085Mar 13, 2024Mar 18, 2024 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
1,500,000——0Mar 13, 2024Mar 18, 2024 ↗View →
IGC
IGC PHARMA, INC.
PURCHASE
CEO
333,334——3,474,761Mar 13, 2024Mar 18, 2024 ↗View →
IGC
IGC PHARMA, INC.
SALE
CEO
16,667——33,333Mar 13, 2024Mar 18, 2024 ↗View →
IGC
IGC PHARMA, INC.
PURCHASE
CEO
233,334——3,141,427Mar 13, 2024Mar 18, 2024 ↗View →
IGC
IGC PHARMA, INC.
SALEGRANT
Gift
200,000——3,526,011Mar 13, 2024Mar 18, 2024 ↗View →
IGC
IGC PHARMA, INC.
SALE
CEO
333,334——666,667Mar 13, 2024Mar 18, 2024 ↗View →
IGC
IGC PHARMA, INC.
SALE
CEO
251,250——783,750Mar 13, 2024Mar 18, 2024 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
1,000,002——0Mar 13, 2024Mar 18, 2024 ↗View →
IGC
IGC PHARMA, INC.
SALEGRANT
Gift
400,000——3,174,761Jun 23, 2023Jun 27, 2023 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
1,000,000——1,000,000Jun 20, 2023Jun 27, 2023 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
50,000——50,000Jun 20, 2023Jun 27, 2023 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
1,035,000——1,035,000Jun 20, 2023Jun 27, 2023 ↗View →
IGC
IGC PHARMA, INC.
SALE
CEO
233,334——466,667Mar 31, 2023Jun 27, 2023 ↗View →
IGC
IGC PHARMA, INC.
SALE
CEO
12,500——12,500Mar 31, 2023Jun 27, 2023 ↗View →
IGC
IGC PHARMA, INC.
PURCHASE
CEO
233,334——3,574,761Mar 31, 2023Jun 27, 2023 ↗View →
IGC
IGC PHARMA, INC.
SALE
CEO
16,667——16,667Mar 31, 2023Jun 27, 2023 ↗View →
IGC
IGC PHARMA, INC.
PURCHASE
CEO
333,333——3,341,427Mar 31, 2023Jun 27, 2023 ↗View →
IGC
IGC PHARMA, INC.
PURCHASE
CEO
16,667——760,751Mar 31, 2023Jun 27, 2023 ↗View →
IGC
IGC PHARMA, INC.
SALE
CEO
333,333——333,333Mar 31, 2023Jun 27, 2023 ↗View →
IGC
IGC PHARMA, INC.
PURCHASE
CEO
16,667——777,418Mar 31, 2023Jun 27, 2023 ↗View →
IGC
IGC PHARMA, INC.
PURCHASE
CEO
200,000——3,308,094Jun 1, 2022Jun 28, 2022 ↗View →
IGC
IGC PHARMA, INC.
SALE
CEO
200,000——3,066,666Jun 1, 2022Jun 28, 2022 ↗View →
IGC
IGC PHARMA, INC.
PURCHASE
CEO
600,000——3,108,094May 31, 2022Jun 28, 2022 ↗View →
IGC
IGC PHARMA, INC.
SALE
CEO
600,000——3,266,666May 31, 2022Jun 28, 2022 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
700,000——700,000May 25, 2022Jun 27, 2023 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
50,000——50,000May 25, 2022Jun 27, 2023 ↗View →
IGC
IGC PHARMA, INC.
PURCHASE
CEO
333,334——2,508,094Mar 21, 2022Jun 28, 2022 ↗View →
IGC
IGC PHARMA, INC.
SALE
CEO
333,334——3,866,666Mar 21, 2022Jun 28, 2022 ↗View →
IGC
IGC PHARMA, INC.
SALE
CEO
16,667——33,333Mar 21, 2022Jun 28, 2022 ↗View →
IGC
IGC PHARMA, INC.
PURCHASE
CEO
16,667——744,084Mar 21, 2022Jun 28, 2022 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
0——2,174,760Dec 20, 2021Dec 23, 2021 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
50,000——50,000Dec 20, 2021Dec 23, 2021 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
3,200,000——4,200,000Dec 20, 2021Dec 23, 2021 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
0——727,417Dec 20, 2021Dec 23, 2021 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
1,000,000——1,000,000Dec 20, 2021Dec 23, 2021 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
50,000——777,417May 13, 2021Sep 15, 2021 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
1,000,000——3,174,760May 13, 2021Sep 15, 2021 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
50,000——777,417May 13, 2021May 13, 2021 ↗View →
IGC
IGC PHARMA, INC.
PURCHASEGRANT
Stock grant
1,000,000——3,774,760May 13, 2021May 13, 2021 ↗View →
IGC
IGC PHARMA, INC.
SALE
Exec. Chairman & CEO
50,000$2.14$107.0K2,774,760Mar 2, 2021Mar 8, 2021 ↗View →
IGC
IGC PHARMA, INC.
SALE
Exec. Chairman & CEO
80,000$2.34$187.0K2,824,760Nov 30, 2020Dec 2, 2020 ↗View →
IGC
IGC PHARMA, INC.
SALEGRANT
Gift
200,000——3,104,760Nov 4, 2020Dec 2, 2020 ↗View →
IGC
IGC PHARMA, INC.
SALEGRANT
Gift
200,000——2,904,760Nov 4, 2020Dec 2, 2020 ↗View →
IGC
IGC PHARMA, INC.
SALEGRANT
Gift
60,000——3,304,760Jun 7, 2020Dec 2, 2020 ↗View →
IGC
IGC PHARMA, INC.
SALEGRANT
Gift
60,000——3,364,760Jun 7, 2020Dec 2, 2020 ↗View →
Other insiders · IGC
Loading peer insiders…
About this filer
CIK 0001047575
ROLE
CEO
PRIMARY
IGC
COMPANIES
1
ACTIVE SINCE
Jun 2020
MARKETPEEL · /INSIDER/0001047575DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback